WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
Enflosina is a long-acting monoclonal antibody that provides direct protection for up to 5 months
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
Subscribe To Our Newsletter & Stay Updated
